Gritstone Presents Data From Individualized Neoantigen Immunotherapy In Colorectal Cancer

Gritstone bio Inc GRTS has announced updated results from the Phase 1/2 study of GRANITE individualized neoantigen immunotherapy in advanced solid tumors.
The immunotherapy is a heterologous prime-boost in combination with Bristol-Myers Squibb Co's BMY Opdivo (nivolumab), and Yervoy (ipilimumab).
The data were presented at the European Society of Medical Oncology (ESMO) Annual Meeting.
In microsatellite-stable colorectal cancer (MSS-CRC) patients, where checkpoint inhibitors have shown minimal activity, GRANITE elicited a 44% molecular response rate in 9 evaluable patients.
Patients who demonstrated molecular response had a median overall survival of over 17 months (median not reached). Those without molecular response exhibited a median overall survival of 7.8 months, consistent with expected outcomes in 3rd line treatment of MSS-CRC.
Multiple patients remained on treatment for over six months with a lack of confirmed disease progression.
Gritstone will advance GRANITE into a Phase 2/3 trial (single protocol) for the maintenance treatment of newly diagnosed metastatic MSS-CRC patients who have completed FOLFOX-bevacizumab induction therapy.
The Company will also conduct a Phase 2 trial evaluating GRANITE in the adjuvant setting for stage 2/3 MSS-CRC patients with ctDNA+ after definitive surgery. The trials will begin in the first half of 2022.
Price Action: GRTS shares are up 5.99% at $14.35 during the premarket session on the last check Friday.
Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga